Article
Oncology
Sun Young Rha, Do-Youn Oh, Patricio Yanez, Yuxian Bai, Min-Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Kai-Keen Shiu, Manuel Gonzalez Fernandez, Jin Li, Maeve A. Lowery, Timucin Cil, Felipe Melo Cruz, Shukui Qin, Suxia Luo, Hongming Pan, Zev A. Wainberg, Lina Yin, Sonal Bordia, Pooja Bhagia, Lucjan S. Wyrwicz
Summary: This study compared the efficacy and safety of pembrolizumab plus chemotherapy with placebo plus chemotherapy for locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma. The results showed that participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity.
Article
Multidisciplinary Sciences
Yang Chen, Keren Jia, Yu Sun, Cheng Zhang, Yilin Li, Li Zhang, Zifan Chen, Jiangdong Zhang, Yajie Hu, Jiajia Yuan, Xingwang Zhao, Yanyan Li, Jifang Gong, Bin Dong, Xiaotian Zhang, Jian Li, Lin Shen
Summary: This paper introduces a multiplexed immunohistochemistry method to predict potential treatment response in gastric cancer patients by considering the proximity of tumor infiltrating immune cells (TIICs). It is found that a single biomarker is not sufficient to identify patients who would benefit from anti-PD-1/PD-L1 therapy due to the complexity of the tumor microenvironment. By establishing a multi-dimensional TIIC signature, the response to immunotherapy and patient survival can be predicted.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Sunho Park, John D. Karalis, Changjin Hong, Jean R. Clemenceau, Matthew R. Porembka, In -Ho Kim, Sung Hak Lee, Sam C. Wang, Jae-Ho Cheong, Tae Hyun Hwang
Summary: In this study, the association between tumor ACTA2 expression and overall survival (OS) as well as response to immune checkpoint inhibitors (ICI) in gastric cancer patients was investigated. It was found that high ACTA2 expression was associated with worse OS and poorer response to ICI treatment. Additionally, ACTA2 expression in cancer-associated fibroblasts (CAF) was found to be specifically related to ICI response.
CLINICAL CANCER RESEARCH
(2023)
Article
Medicine, General & Internal
Merel J. M. van Velzen, Michelle Braemer, Grard A. P. Nieuwenhuijzen, Johanna W. van Sandick, Peter D. Siersema, Jelle P. Ruurda, Marcel Verheij, Manon C. W. Spaander, Laurens V. Beerepoot, Nadia Haj Mohammad, Hanneke W. M. van Laarhoven, Rob H. A. Verhoeven
Summary: This study aimed to analyze the trends in incidence, staging, and treatment of gastric cancer. The results showed a decrease in incidence, more accurate staging, a shift in treatment modalities, and improved patient survival.
Editorial Material
Oncology
Naureen Starling, David Cunningham
Summary: We discuss how Pyrhonen's paper has become a catalyst for defining systemic therapy approaches in gastric cancer, and the evolution of the field in the last two decades, including sequential, targeted, and more recently immune-directed therapies. We also explore the potential of further development to transform the survival rates in this cancer of high unmet need.
BRITISH JOURNAL OF CANCER
(2023)
Article
Oncology
Meike Kohlruss, Katja Ott, Bianca Grosser, Moritz Jesinghaus, Julia Slotta-Huspenina, Alexander Novotny, Alexander Hapfelmeier, Thomas Schmidt, Matthias M. Gaida, Wilko Weichert, Gisela Keller
Summary: This study analyzed 717 patients with gastric/gastro-esophageal adenocarcinomas to investigate sex- and age-specific differences in overall survival (OS) and response to neoadjuvant chemotherapy (CTx), considering tumor molecular subtypes. Females, particularly those treated with CTx, demonstrated significantly increased OS, with women with high microsatellite instability (MSI-H) tumors showing the best survival among the CTx patients. This suggests that sex plays a role in the overall survival of gastric/gastro-esophageal cancer patients, especially those receiving neoadjuvant CTx.
Article
Oncology
Patrick S. Plum, Aylin Pamuk, Atakan G. Barutcu, Christoph Mallmann, Emanuel Niesen, Felix Berlth, Thomas Zander, Seung-Hun Chon, Stefan P. Moenig, Alexander Quaas, Christiane J. Bruns, Arnulf H. Hoelscher, Hakan Alakus
Summary: The diagnosis and treatment of gastric and gastroesophageal junction cancer have undergone significant changes in the past two decades. A retrospective cohort study conducted in a European center for upper gastrointestinal surgery examined how clinical reality has changed for these patients outside of clinical trials.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yanez, Ning Li, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan S. Wyrwicz, Jianming Xu, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Sukrut Shah, Pooja Bhagia, Hyun Cheol Chung
Summary: The study results demonstrate that adding pembrolizumab to trastuzumab and chemotherapy significantly reduces tumor size, induces complete responses in some patients, and improves objective response rate in HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Article
Oncology
Stefano Cascinu, Gyorgy Bodoky, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, Gunnar Folprecht, Sumitra Ananda, Gustavo Girotto, Zev A. Wainberg, Maria Luisa Limon Miron, Jaffer Ajani, Ran Wei, Astra M. Liepa, Roberto Carlesi, Michael Emig, Atsushi Ohtsu
Summary: In the RAINBOW study, ramucirumab plus paclitaxel showed higher objective response rate than the control arm in previously treated advanced gastric or gastroesophageal junction adenocarcinoma patients, with longer response duration, leading to improved quality of life.
Article
Medicine, General & Internal
Kohei Shitara, Florian Lordick, Yung-Jue Bang, Peter Enzinger, David Ilson, Manish A. Shah, Eric Van Cutsem, Rui-Hua Xu, Giuseppe Aprile, Jianming Xu, Joseph Chao, Roberto Pazo-Cid, Yoon-Koo Kang, Jianning Yang, Diarmuid Moran, Pranob Bhattacharya, Ahsan Arozullah, Jung Wook Park, Mok Oh, Jaffer A. Ajani
Summary: Zolbetuximab in combination with mFOLFOX6 significantly prolongs progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma, with good safety profile.
Article
Oncology
Koichi Sawaki, Mitsuro Kanda, Hayato Baba, Yoshikuni Inokawa, Norifumi Hattori, Masamichi Hayashi, Chie Tanaka, Yasuhiro Kodera
Summary: The study identified GABRD as a novel regulator of gastric cancer cell growth and function. High expression of GABRD mRNA in primary gastric cancer tissue was associated with poor prognosis. Anti-GABRD antibodies inhibited gastric cancer cell proliferation in vitro and decreased tumor nodule size in a mouse model, suggesting that GABRD may be a potential therapeutic target for gastric cancer.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Raluca Maria Fostea, Hendrik-Tobias Arkenau
Summary: Trifluridine/tipiracil is a compound drug approved for the treatment of chemorefractory colorectal, gastric, and gastroesophageal junction cancers. Promising results have been observed, leading to further studies investigating its use in combination with other standard of care agents to improve patient survival rates.
Article
Oncology
Daisuke Takahari, Hitoshi Katai, Atsuo Takashima, Naoki Izawa, Naoki Ishizuka, Manabu Ohashi, Shinya Mikami, Takeru Wakatsuki, Izuma Nakayama, Keisho Chin, Satoshi Ida, Koshi Kumagai, Souya Nunobe, Satoru Iwasa, Hirokazu Shoji, Takeyuki Wada, Ayako Doi, Takaki Yoshikawa, Takeshi Sano, Narikazu Boku, Kensei Yamaguchi
Summary: This study investigated the feasibility of perioperative chemotherapy with TAS-118 plus oxaliplatin in patients with locally advanced gastric cancer. The completion rate of preoperative chemotherapy was 88.9% and the R0 resection rate was 95.6%. The completion rates of postoperative chemotherapy were 90.9% (TAS-118 monotherapy) and 80.0% (TAS-118 plus oxaliplatin). The 3-year recurrence-free and overall survival rates were 66.7% and 84.4%, respectively.
Article
Oncology
Charles S. Fuchs, Mustafa Ozguroglu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandala, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesinski, Christian Caglevic, Hyun C. Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter Thuss-Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie-Schin Shih, Kohei Shitara
Summary: In this long-term analysis, second-line pembrolizumab did not significantly improve overall survival but was associated with higher 24-month OS rates than paclitaxel in the CPS>=1 population. Pembrolizumab also increased overall survival benefit with PD-L1 enrichment among patients with PD-L1-positive gastric/GEJ cancer and led to fewer treatment-related adverse events (TRAEs) compared to paclitaxel.
Article
Oncology
Chih-Chieh Yen, Yi-Hsin Yang, Hsiu-Ying Ku, Huang-Ming Hu, Su-Shun Lo, Hung-Chi Chang, Yee Chao, Jen-Shi Chen, Hsiu-Po Wang, Tsang-En Wang, Li-Yuan Bai, Ming-Shiang Wu, Chia-Jui Yen, Li-Tzong Chen, Yan-Shen Shan
Summary: A population-based study in Taiwan investigated the impact of preoperative waiting time (PreWT) on the prognosis of patients with Stage II-III gastric cancer. The study found that PreWT of 49-118 days did not independently correlate with a poor prognosis in these patients. This suggests that a window period for preoperative therapies and patient optimization is justified.
